The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causative agent of the coronavirus disease 2019 (COVID-19), is still circulating and posing a health threat to the global population. Its main protease (M) constitutes an excellent target for the development of antivirals due to its indispensable role in the viral replication cycle. In this work, we employed a sequential approach to identify a potent azapeptide-based M inhibitor. Starting from a series of small-molecule peptidomimetics, identical in their scaffold but equipped with different cysteine-reactive groups, we identified auspicious warheads. The combination of selected moieties with an optimized, previously described P1-P4 azapeptide structure resulted in a potent M inactivator (12) with a k/K value of 78,900 Ms. The chloracetohydrazide derivative 12 exhibited antiviral activity (EC = 0.47 µM), no cytotoxicity, and plasma stability. The molecular interaction of 12 with M was elucidated by an X-ray crystal structure. A thioether linkage was generated through a nucleophilic substitution of chloride by the active-site thiolate, giving rise to irreversible inhibition.
Keywords: SARS‐CoV‐2 main protease, azapeptides, chloroacetohydrazides, peptidomimetics, protease inhibitors
Archiv der Pharmazie
Journal Article
English
41431928
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.